

Selected Innovative Medicines in Development as of January 23, 2024



Oncology (1 of 2)

RYBREVANT / lazertinib

Non Small Cell Lung Cancer (MARIPOSA)

CARVYKTI (Ciltacabtagene autoleucel)

Relapsed Refractory multiple myeloma w/1-3 PL (CARTITUDE-4)

TECVAYLI (teclistamab)

Relapsed Refractory Multiple Myeloma CD38 exposed (MajesTEC-9)

TALVEY (talquetamab)

Relapsed Refractory Multiple Myeloma A-CD38 Naïve (MonumentAL-3)

TAR-200 (RIS/gemcitabine plus cetrelimab)

Non Muscle Invasive Bladder Cancer BCG-naïve High Risk (SunRISe-3)

DARZALEX (daratumumab)

Frontline multiple myeloma transplant ineligible (CEPHEUS)

ERLEADA (apalutamide)

Localized Prostate Cancer (ATLAS)

RYBREVANT (amivantamab)

Subcutaneous (PALOMA-3)

IMBRUVICA (ibrutinib)

Frontline Chronic Lymphocytic Leukemia (I + V fixed duration) (GLOW)

RYBREVANT / lazertinib

Non Small Cell Lung Cancer 2L (MARIPOSA-2)

TECVAYLI (teclistamab)

TE NDMM maintenance (MajesTEC-4)

AKEEGA (niraparib/abiraterone)

M1 Metastatic Castration-Sensitive Prostate Cancer (AMPLITUDE)

TAR-200 (RIS/gemcitabine plus cetrelimab)

Muscle Invasive Bladder Cancer (SunRISe-2)

DARZALEX (daratumumab)

Smoldering Multiple Myeloma (AQUILA)

CARVYKTI (Ciltacabtagene autoleucel)

Frontline Multiple Myeloma Transplant Eligible vs ASCT (CARTITUDE-6)

TAR-200 (RIS/gemcitabine plus cetrelimab)

Non Muscle Invasive Bladder Cancer (SunRISe-1)

BALVERSA (erdafitinib)

Urothelial Cancer (THOR)

RYBREVANT (amivantamab)

Frontline Non Small Cell Lung Cancer in combination with chemotherapy (PAPILLON)

TECVAYLI (teclistamab)

Multiple Myeloma 1-3PLs (MajesTEC-3)

IMBRUVICA (ibrutinib)

Relapsed Refractory patients with Mantle Cell Lymphoma in combination with venetoclax (SYMPATICO)

DARZALEX (daratumumab)

Frontline multiple myeloma transplant eligible (PERSEUS)

ERLEADA (apalutamide)

High Risk Prostate Cancer (PROTEUS)

CARVYKTI (Ciltacabtagene autoleucel)

Frontline Multiple Myeloma TNI (CARTITUDE-5)

JNJ-8343

Prostate Cancer

Oncology (2 of 2)

VAC85135

Hematological Malignancies

JNJ-1493

Hematological Malignancies

JNJ-8114

Prostate Cancer

JNJ-6617

Hematological Malignancies

erdafitinib

Intravesical Delivery System for Localized Bladder Cancer

JNJ-9401

Prostate Cancer

JNJ-5322

Multiple Myeloma

JNJ-6420

Prostate Cancer

JNJ-9968

Hematological Malignancies

JNJ-8543

Hematological Malignancies

JNJ-8780

Hematological Malignancies

JNJ-4681

Hematological Malignancies

STELARA (ustekinumab)

Pediatric Juvenile Psoriatic Arthritis

TREMFYA (guselkumab)

Crohn's Disease Subcutaneous Induction (GRAVITI)

TREMFYA (guselkumab)

Pediatric Psoriasis

STELARA (ustekinumab)

Pediatric Crohn's Disease

JNJ-2113

Psoriasis

nipocalimab

Hemolytic Disease of the Fetus and Newborn

nipocalimab Combination Therapy

Rheumatoid Arthritis

JNJ-4804 Combination Therapy

Ulcerative Colitis

TREMFYA (guselkumab)

Pediatric Juvenile Psoriatic Arthritis

TREMFYA (guselkumab)

Psoriatic Arthritis Structural Damage

TREMFYA (guselkumab)

Crohn's Disease (GALAXI)

SIMPONI (golimumab)

Pediatric Ulcerative Colitis

TREMFYA (guselkumab)

Giant Cell Arteritis

nipocalimab

Sjogren's Disease

JNJ-4804 Combination Therapy

Crohn's Disease

JNJ-2113

Ulcerative Colitis

TREMFYA (guselkumab)

Ulcerative Colitis Subcutaneous Induction (ASTRO)

TREMFYA (guselkumab)

Ulcerative Colitis Monotherapy (QUASAR)

STELARA (ustekinumab)

Pediatric Ulcerative Colitis

nipocalimab

Warm Autoimmune Hemolytic Anemia

nipocalimab

Idiopathic Inflammatory Myopathy

nipocalimab

Systemic Lupus Erythematosus

JNJ-4804 Combination Therapy

Psoriatic Arthritis

JNJ-4703

Atopic Dermatitis

JNJ-1459

Psoriasis

JNJ-9280

Inflammatory Bowel Disease

JNJ-4703

Rheumatoid Arthritis

seltorexant

Adjunctive treatment for major depressive disorder with insomnia symptoms

aticaprant

Adjunctive Major Depressive Disorder

nipocalimab

Generalized Myasthenia Gravis Pediatrics

JNJ-1813

Epilepsy

nipocalimab

Chronic Inflammatory Demyelinating Polyneuropathy

seltorexant

Probable Alzheimer's with clinically significant agitation/aggression

SPRAVATO (esketamine)

Major Depressive Disorder with Suicidal Ideation Pediatrics

JNJ-0376

Parkinson's Disease

nipocalimab

Generalized Myasthenia Gravis

posdinemab

Alzheimer's Disease

P2X7 antagonist

Bipolar Depression

VAC20121 *

Alzheimer's Disease

Select Other Areas

CABENUVA

HIV Adolescents

OPSYNVI (macitentan/tadalafil STCT)

Pulmonary Arterial Hypertension (A DUE)

macitentan

Pulmonary Arterial Hypertension 75mg (UNISUS)

milvexian (Factor Xla)

Acute Coronary Syndrome

JNJ-1802

Dengue Prophylaxis

OPSUMIT (macitentan)

Pediatric Pulmonary Arterial Hypertension (TOMORROW)

UPTRAVI (selexipag)

Pediatric Pulmonary Arterial Hypertension (SALTO)

VAC52416

Multivalent ExPEC Vaccine

milvexian (Factor Xla)

Secondary Stroke Prevention

prostacyclin receptor agonist

Pulmonary Arterial Hypertension

EDURANT (rilpivirine)

HIV pediatric 2-12 year old

RPGR Gene Therapy

Retinitis Pigmentosa

milvexian (Factor Xla)

Atrial Fibrillation

JNJ-1887 sCD59

Geographic Atrophy

JNJ-0237

Autosomal Dominant Polycystic Kidney Disease

*This information is as of January 23, 2024 to the best of the Company's knowledge. Johnson & Johnson assumes no obligation to update this information. *AC Immune ACI-35.030. Strategic Partnerships, Collaborations, and Licensing arrangements - XARELTO: Bayer; milvexian: Bristol Myers Squibb; X-Linked Retinitis Pigmentosa (AAV-RPGR) and Achromatopsia Gene Therapies (CNGA3 and CNGB3): MeiraGTX; JNJ-1887: Hemera Biosciences; PNPLA3: Arrowhead Pharmaceuticals; COMPLERA / EVIPLERA, ODEFSEY, SYMTUZA, PREZCOBIX / REZOLSTA FDC: Gilead Sciences; JULUCA and Long acting HIV injectible treatment regimen of rilpivirine and cabotegravir: ViiV Healthcare; Cloudbreak antiviral conjugates (AVCs); ExPEC: Sanofi; REMICADE and SIMPONI/SIMPONI ARIA: Schering-Plough (Ireland) Company, a subsidiary of Merck & Co., Inc. and Mitsubishi Tanabe Pharma Corporation; TREMFYA: MorphoSys AG; JNJ-2113: Protagonist Therapeutics; Tau Vaccine: AC Immune SA; JNJ-1813: Addex Pharmaceuticals; IMBRUVICA: Pharmacyclics, LLC, an AbbVie company; ZYTIGA: BTG International; VELCADE: Millennium, The Takeda Oncology Company; DARZALEX and DARZALEX FASPRO; Genmab A/S; BALVERSA: Astex Pharmaceuticals; ERLEADA: Regents of California and Memorial Sloan Kettering; CARVYKTI: Legend Biotech; AKEEGA: TESARO, an oncology-focused business within GSK; lazertinib: Yuhan Corporation; Duobody Platform bispecific antibody programs: Genmab A/S; ENHANZE platform; Halozyme Therapeutics; XmAb CD28 bispecific antibodies; Xencor; iPSC-derived chimeric antigen receptor (CAR) NK and CAR T-cell product candidates: Fate Therapeutics; UPTRAVI and OPSUMIT: Nippon Shinyaku (co-promotion in Japan); JNJ-1459: X-CHEM; JNJ-1802: KU Leuven Rega Institute, the KU Leuven Centre for Drug Design and Discovery (CD3), Department of Virology at the Biomedical Primate Research Centre, Department of Infectious Diseases at Heidelberg University, Sealy Institute for Vaccine Sciences at the University of Texas Medical Branch Health (UTMB), Unité des Virus Émergents at Aix-Marseille University and the Walter Reed Army Institute of Research.